Related references
Note: Only part of the references are listed.Combination and Intermittent Therapy Based on Pegylated Interferon Alfa-2a for Chronic Hepatitis B with Nucleoside (Nucleotide) Analog-Experienced Resulting in Hepatitis B Surface Antigen Clearance: A Case Report
Yan-Jie Lin et al.
VIRAL IMMUNOLOGY (2022)
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B
Valentina Svicher et al.
GUT (2021)
Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B
Akihiro Matsumoto et al.
JOURNAL OF GASTROENTEROLOGY (2020)
The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone
Sheng Lin et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2020)
Current state-of-the-art pharmacotherapy for the management of hepatitis B infection
Hans L. Tillmann et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B
Ming-Lun Yeh et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B
Satoru Hagiwara et al.
ANTIVIRAL THERAPY (2018)
Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatits B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study)
Dae Won Jun et al.
CHINESE MEDICAL JOURNAL (2018)
Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection
Klaus Klumpp et al.
GASTROENTEROLOGY (2018)
Share Paper
